// App-Quantinova.ai

Mo1879 : Response and Remission Rates With Up to 3 Years of Vedolizumab Treatment in Patients With Crohn's Disease

Researchers

Presenter

  • Brian G. Feagan

Principal Investigators

  • Reema Mody

  • Alessandro Previtali

  • Brihad Abhyankar

Medical Centers

  • University Hospital Gasthuisberg, Leuven, Belgium

  • Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada

Locations

  • Canada

  • Belgium

Companies

  • Takeda Pharmaceutica

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Ulcerative colitis

  • Crohn's disease

  • Anal fistula

Biomarkers

  • N/A

Drug/Treatment

  • Entyvio

Outcome

  • Unknown

Study Design

  • open label

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved